Effects of Adjunct Low-Dose Vitamin D on Relapsing-Remitting Multiple Sclerosis Progression: Preliminary Findings of a Randomized Placebo-Controlled Trial

Table 4

Comparison of Expanded Disability Status Scale (EDSS) and relapses in 50 patients with relapsing-remitting multiple sclerosis before and 2, 4, 6, 8, 10, 12 months after treatment with low-dose vitamin D and placebo.

Characteristics	Treatment group		Differences (95% CI)
	Vitamin D (𝑛=25) Mean (SD)	Placebo (𝑛=25) Mean (SD)
	EDSS
At baseline	1.60 (0.72)	1.70 (1.22)	−0.10 (−0.67, 0.47)
After 2 months	1.56 (0.70)	1.70 (1.22)	−0.14 (−0.71, 0.43)
After 4 months	1.56 (0.70)	1.74 (1.23)	−0.18 (−0.75, 0.39)
After 6 months	1.60 (0.70)	1.84 (1.32)	−0.24 (−0.84, 0.36)
After 8 months	1.54 (0.66)	1.90 (1.42)	−0.36 (−0.99, 0.27)
After 10 months	1.63 (0.70)	1.94 (1.41)	−0.31 (−0.94, 0.32)
After 12 months	1.63 (0.70)	1.94 (1.41)	−0.31 (−0.94, 0.32)
Difference at 12-months and baseline	0.03 (0.36)	0.24 (0.39)	−0.21 (−0.45, −0.3)*
	Relapses
At baseline	1.04 (0.20)	1.04 (0.20)	0.00 (−0.11, 0.11)
After 12 months	0.32 (0.48)	0.40 (0.58)	−0.08 (−0.38, 0.22)
Difference at 12-months and baseline	−0.72 (0.54)	−0.64 (0.64)	−0.08 (−0.42, 0.26)

^∗𝑃<0.05. CI: confidence interval.